Watchlist Price Alert

Aeglea BioTherapeutics In... (AGLE)

NASDAQ: AGLE · Real-Time Price · USD

12.01

0.75 (6.66%)

At close: Nov 27, 2023, 9:00 PM

Aeglea BioTherapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Net Income	-83.81M	-65.8M	-80.89M	-78.25M	-44.35M	-27.24M	-21.7M
Depreciation & Amortization	1.57M	1.58M	996K	418K	293K	249K	132K
Stock-Based Compensation	7.11M	8.04M	6.26M	4.88M	4.28M	2.49M	1.22M
Other Working Capital	-2.86M	768K	-2M	4.52M	-20K	-362K	1.46M
Other Non-Cash Items	496K	434K	619K	478K	67K	78K	55K
Deferred Income Tax	n/a	204K	-213K	-314K	314K	84K	-45K
Change in Working Capital	-5.5M	1.83M	-2.54M	7.1M	7.2M	-198K	1.45M
Operating Cash Flow	-80.14M	-53.72M	-75.78M	-65.69M	-32.19M	-24.61M	-18.84M
Capital Expenditures	-38K	-573K	-4.28M	-1.49M	-422K	-619K	-212K
Cash Acquisitions	428K	-344K	-286K	504K	907K	n/a	n/a
Purchase of Investments	-39.5M	-133.08M	-129M	-91.93M	-62.18M	-64.11M	-20.39M
Sales Maturities Of Investments	96.55M	111.03M	125.68M	91.68M	47.37M	42.2M	8.45M
Other Investing Acitivies	-428K	344K	286K	-504K	-907K	n/a	80K
Investing Cash Flow	57.01M	-22.62M	-7.6M	-1.74M	-15.23M	-22.53M	-12.08M
Debt Repayment	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	42.68M	1.39M	154.51M	65.72M	57.07M	12.21M	49.37M
Financial Cash Flow	42.68M	1.39M	154.51M	65.72M	57.07M	12.21M	49.37M
Net Cash Flow	19.44M	-74.96M	71.18M	-1.71M	9.64M	-34.93M	18.45M
Free Cash Flow	-80.18M	-54.29M	-80.06M	-67.18M	-32.62M	-25.23M	-19.05M